76 related articles for article (PubMed ID: 38397112)
21. Post-synaptic specialization of the neuromuscular junction: junctional folds formation, function, and disorders.
Zou S; Pan BX
Cell Biosci; 2022 Jun; 12(1):93. PubMed ID: 35718785
[TBL] [Abstract][Full Text] [Related]
22. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Lim M; Weller M; Idbaih A; Steinbach J; Finocchiaro G; Raval RR; Ansstas G; Baehring J; Taylor JW; Honnorat J; Petrecca K; De Vos F; Wick A; Sumrall A; Sahebjam S; Mellinghoff IK; Kinoshita M; Roberts M; Slepetis R; Warad D; Leung D; Lee M; Reardon DA; Omuro A
Neuro Oncol; 2022 Nov; 24(11):1935-1949. PubMed ID: 35511454
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A; Brandes AA; Carpentier AF; Idbaih A; Reardon DA; Cloughesy T; Sumrall A; Baehring J; van den Bent M; Bähr O; Lombardi G; Mulholland P; Tabatabai G; Lassen U; Sepulveda JM; Khasraw M; Vauleon E; Muragaki Y; Di Giacomo AM; Butowski N; Roth P; Qian X; Fu AZ; Liu Y; Potter V; Chalamandaris AG; Tatsuoka K; Lim M; Weller M
Neuro Oncol; 2023 Jan; 25(1):123-134. PubMed ID: 35419607
[TBL] [Abstract][Full Text] [Related]
24. Practical "1-2-3-4-Day" Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study.
Kimura S; Toyoda K; Yoshimura S; Minematsu K; Yasaka M; Paciaroni M; Werring DJ; Yamagami H; Nagao T; Yoshimura S; Polymeris A; Zietz A; Engelter ST; Kallmünzer B; Cappellari M; Chiba T; Yoshimoto T; Shiozawa M; Kitazono T; Koga M;
Stroke; 2022 May; 53(5):1540-1549. PubMed ID: 35105180
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638384
[TBL] [Abstract][Full Text] [Related]
26. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
27. CD8
Reina-Campos M; Scharping NE; Goldrath AW
Nat Rev Immunol; 2021 Nov; 21(11):718-738. PubMed ID: 33981085
[TBL] [Abstract][Full Text] [Related]
28. Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis.
Zhang JJY; Lee KS; Voisin MR; Hervey-Jumper SL; Berger MS; Zadeh G
Neurooncol Adv; 2020; 2(1):vdaa111. PubMed ID: 33063012
[TBL] [Abstract][Full Text] [Related]
29. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes.
Friebel E; Kapolou K; Unger S; Núñez NG; Utz S; Rushing EJ; Regli L; Weller M; Greter M; Tugues S; Neidert MC; Becher B
Cell; 2020 Jun; 181(7):1626-1642.e20. PubMed ID: 32470397
[TBL] [Abstract][Full Text] [Related]
30. Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells.
Klemm F; Maas RR; Bowman RL; Kornete M; Soukup K; Nassiri S; Brouland JP; Iacobuzio-Donahue CA; Brennan C; Tabar V; Gutin PH; Daniel RT; Hegi ME; Joyce JA
Cell; 2020 Jun; 181(7):1643-1660.e17. PubMed ID: 32470396
[TBL] [Abstract][Full Text] [Related]
31. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
32. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
33. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
34. The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis.
Bergmann N; Delbridge C; Gempt J; Feuchtinger A; Walch A; Schirmer L; Bunk W; Aschenbrenner T; Liesche-Starnecker F; Schlegel J
Front Oncol; 2020; 10():494. PubMed ID: 32391260
[TBL] [Abstract][Full Text] [Related]
35. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hogg D; Hill A; Márquez-Rodas I; Haanen J; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bastholt L; Rizzo JI; Balogh A; Moshyk A; Hodi FS; Wolchok JD
N Engl J Med; 2019 Oct; 381(16):1535-1546. PubMed ID: 31562797
[TBL] [Abstract][Full Text] [Related]
36. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
[TBL] [Abstract][Full Text] [Related]
37. The deubiquitinase Otub1 controls the activation of CD8
Zhou X; Yu J; Cheng X; Zhao B; Manyam GC; Zhang L; Schluns K; Li P; Wang J; Sun SC
Nat Immunol; 2019 Jul; 20(7):879-889. PubMed ID: 31182807
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.
Tanaka Y; Nakazawa T; Nakamura M; Nishimura F; Matsuda R; Omoto K; Shida Y; Murakami T; Nakagawa I; Motoyama Y; Morita H; Tsujimura T; Nakase H
PLoS One; 2019; 14(3):e0212455. PubMed ID: 30840664
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
